Showing results (521-530 of 601) with videos related to
Sort By:
Pageof 61
Multiple Sclerosis (Houndmills, Basingstoke, England)|March 10, 2018
Effect of HLA-DRB1 alleles and genetic variants on the development of neutralizing antibodies to interferon beta in the BEYOND and BENEFIT trialsDorothea Buck, Till Fm Andlauer, Wilmar Igl, et al.Ebiomedicine|July 3, 2024
Identification of disease phenotypes in acetylcholine receptor-antibody myasthenia gravis using proteomics-based consensus clusteringChristopher Nelke, Christina B Schroeter, Sumanta Barman, et al.The Lancet. Neurology|May 17, 2024
Safety and efficacy of inebilizumab for the treatment of neuromyelitis optica spectrum disorder: end-of-study results from the open-label period of the N-MOmentum trialBruce A C Cree, Ho Jin Kim, Brian G Weinshenker, et al.Neurology|October 28, 2018
Racial differences in neuromyelitis optica spectrum disorderSu-Hyun Kim, Maureen A Mealy, Michael Levy, et al.Multiple Sclerosis (Houndmills, Basingstoke, England)|June 7, 2023
Attack adjudication in neuromyelitis optica spectrum disorder: Substantiation of criteria by magnetic resonance imaging and biomarkers in N-MOmentumBrian G Weinshenker, Dean M Wingerchuk, Ari J Green, et al.Multiple Sclerosis (Houndmills, Basingstoke, England)|December 14, 2012
Effects of early treatment with glatiramer acetate in patients with clinically isolated syndromeGiancarlo Comi, Vittorio Martinelli, Mariaemma Rodegher, et al.Neurology|August 25, 2017
Alemtuzumab CARE-MS II 5-year follow-up: Efficacy and safety findingsAlasdair J Coles, Jeffrey A Cohen, Edward J Fox, et al.Journal of Neuroinflammation|November 6, 2019
Monitoring retinal changes with optical coherence tomography predicts neuronal loss in experimental autoimmune encephalomyelitisAndrés Cruz-Herranz, Michael Dietrich, Alexander M Hilla, et al.Lancet (London, England)|November 6, 2012
Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trialAlasdair J Coles, Cary L Twyman, Douglas L Arnold, et al.Neurology|August 25, 2017
Alemtuzumab CARE-MS I 5-year follow-up: Durable efficacy in the absence of continuous MS therapyEva Havrdova, Douglas L Arnold, Jeffrey A Cohen, et al.Pageof 61